The Opportunity

Our Patents

    1. Pondera COPD/Asthma Patent (U.S. Patent  No. 8,617,577, December 31, 2013) A method to safely and effectively treat asthma or chronic obstructive pulmonary disease in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone in an amount of about 1 microgram to about 500 micrograms; and (b) administering an Endorphin Enhancer, wherein the Endorphin Enhancer is selected from the group consisting of theophylline, roflumilast, ibudilast, cilomilast, zaprinast, rolipram, methylxanthine.
    2. Pondera Anxiety Disorder patent (U.S. Patent No. 8,741,319, June 3, 2013) A method to safely and effectively treat anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering a Receptor Switcher to the subject, wherein the Receptor Switcher is naltrexone; and (b) administering at least one Endorphin Enhancer to the subject, wherein the Endorphin Enhancer is roflumilast.
    3.  Pondera Endorphinate Patent.  (US Patent No. 8,372,414;  February 12, 2013) A method to safely and effectively treat Anxiety conditions, symptoms and/or disorders in a subject in need comprising: (a) administering at least one Receptor Switcher to the subject, wherein the receptor switcher is N-acetyl cysteine; and (b) administering at least one Endorphin Enhancer to the subject, wherein the endorphin enhancer is a compound comprising caffeine.
  • Partnership and licensing Agreements. Pondera will consider entering into appropriate and mutually beneficial partnership and licensing agreements in the United States, Canada, Europe, South America, Asia and Africa for Endorphinate® commercialization.
  • Manufacturing. Pondera is seeking manufacturers in the United States, Canada, Europe, South America, Asia and Africa to produce Endorphinate® for these markets.
  • Distribution and sales. Pondera is seeking to establish distribution and sales relationship with companies in the United States, Canada, Europe, South America, Asia and Africa to distribute and sell Endorphinate®.

For access to Confidential Financial, Scientific, Research and Strategic Partnership Information,  please contact:

William E. Crain, President & CEO
Pondera Pharmaceuticals, Inc.
209 Chadsey Road, Pownal ME 04069
207-688-6444 
william@ponderapharma.com